Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Disc Medicine, Inc.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 1 in 2023
Applications published
27
8 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Disc Medicine, Inc. its own name
US, as the owner printed on each patent
10 publishedDisc Medicine, Inc. its own name
named as the applicant on its applications, in US
11 publishedGemini Therapeutics Inc. a former name
named as the applicant on its applications, in US
6 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 16, 2025 | 12,497,452 | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis | Pharmaceuticals | Disc Medicine, Inc. |
| Sep 30, 2025 | 12,428,415 | Matriptase 2 inhibitors and uses thereof | Organic fine chemistry | Disc Medicine, Inc. |
| Jul 22, 2025 | 12,365,729 | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis | Pharmaceuticals | Disc Medicine, Inc. |
| Nov 14, 2023 | 11,813,257 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | Pharmaceuticals | Disc Medicine, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 9, 2025 | 2025/0312445 | METHODS FOR TREATING BLOOD LOSS CONDITIONS | Pharmaceuticals | Disc Medicine, Inc. |
| Oct 2, 2025 | 2025/0304678 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | Pharmaceuticals | Disc Medicine, Inc. · patent 12,497,452 granted from it |
| Oct 2, 2025 | 2025/0302823 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | Pharmaceuticals | Disc Medicine, Inc. |
| Aug 21, 2025 | 2025/0262204 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Pharmaceuticals | Disc Medicine, Inc. |
| Aug 7, 2025 | 2025/0248995 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | Pharmaceuticals | Disc Medicine, Inc. |
| Jul 17, 2025 | 2025/0228827 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Pharmaceuticals | Disc Medicine, Inc. |
| May 1, 2025 | 2025/0136718 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | Pharmaceuticals | Disc Medicine, Inc. |
| Mar 13, 2025 | 2025/0084162 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | Pharmaceuticals | Disc Medicine, Inc. · patent 12,365,729 granted from it |
| Dec 19, 2024 | 2024/0417458 | METHODS FOR TREATING ANEMIA OF KIDNEY DISEASE | Pharmaceuticals | Disc Medicine, Inc. |
| Dec 5, 2024 | 2024/0400553 | AMINE BASED MATRIPTASE 2 INHIBITORS AND USES THEREOF | Organic fine chemistry | Disc Medicine, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Biotechnology 1 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.